Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Lyndra appoints Adam Sayer as new CEO and president
The company’s upcoming pivotal safety trial for LYN-005 is scheduled to begin in the first half of 2025. Credit: PeopleImages.com – Yuri A/Shutterstock. Lyndra Therapeutics